Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge

Iterum Therapeutics ( (ITRM) ) has issued an announcement.

On December 11, 2025, Iterum Therapeutics received a notification from Nasdaq indicating that it no longer meets the listing requirements due to its market value of listed securities falling below $35 million for 30 consecutive business days. The company has until June 9, 2026, to regain compliance, or it risks delisting. Additionally, Iterum was previously notified on August 25, 2025, about non-compliance with the minimum bid price rule, with a deadline of February 23, 2026, to address this issue. Failure to meet these requirements could lead to delisting, although the company may appeal any delisting decisions.

The most recent analyst rating on (ITRM) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.

Spark’s Take on ITRM Stock

According to Spark, TipRanks’ AI Analyst, ITRM is a Underperform.

Iterum Therapeutics faces significant financial challenges with ongoing net losses and cash flow issues, despite positive developments such as FDA approval of ORLYNVAH. The technical indicators suggest weak market momentum, and valuation metrics reflect poor investment attractiveness. The potential market for ORLYNVAH and improved financial performance are notable positives, but strategic uncertainties and financial obligations weigh heavily on the stock’s outlook.

To see Spark’s full report on ITRM stock, click here.

More about Iterum Therapeutics

Iterum Therapeutics plc operates in the pharmaceutical industry, focusing on the development and commercialization of anti-infective treatments. The company primarily targets unmet medical needs in the area of serious bacterial infections.

Average Trading Volume: 936,890

Technical Sentiment Signal: Sell

Current Market Cap: $24.28M

For a thorough assessment of ITRM stock, go to TipRanks’ Stock Analysis page.